Fennec Pharmaceuticals (FRX) AI Stock Analysis

Company Guidance

Management reiterated 2026 operating guidance of roughly $50.0M in total cash OpEx, with about $20–22M (≈40%) to be recorded in H2 2026; cash and cash equivalents were $41.2M as of June 30 (a $1.0M increase in Q2), and the company expects Q3 ending cash to be lower than Q2 but positive cash generation in Q4 and a positive year‑end cash position, stating June 30 cash plus projected PEDMARK revenues should fund the business under the current plan. Key Q2 financials and profitability trends cited: net product sales of $17.1M (≈78% YoY vs. $9.7M), OpEx (R&D + SG&A excl. stock comp) ≈$13.6M (up ≈$3.6M YoY), record non‑GAAP adjusted EBITDA ≈$2.8M (vs. a $1.2M loss a year ago), and EPS $0.05 (vs. -$0.11). Operational and commercial metrics they expect to drive further growth include expanding prescriber targets from ~1,300 to ~5,000, a 280% increase in sales calls in Q2, unique HCP reach +63%, affiliated sites +72%, >50% of business from home infusion, double‑digit demand growth Q2 over Q1, record AYA enrollment in Q2, and all‑time highs in July for completed infusions, new patient enrollments, active patients on therapy and new customers — trends management expects to carry into Q3 and to drive meaningful increases in operating income and adjusted EBITDA.